Modified virus attacks tough ovarian cancer in new trial
NCT ID NCT05271318
Summary
This early-stage trial is testing whether a specially engineered virus called TILT-123, when combined with existing cancer drugs, is safe and potentially effective for women with advanced ovarian cancer that has stopped responding to standard platinum chemotherapy. The virus is designed to infect and kill cancer cells while also stimulating the immune system to fight the cancer. The study will enroll about 29 participants to find the right dose and check for side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PLATINUM-RESISTANT FALLOPIAN TUBE CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Docrates Cancer Center
ACTIVE_NOT_RECRUITINGHelsinki, 00180, Finland
-
Mayo Clinic
RECRUITINGRochester, Minnesota, 55905, United States
Contact
Contact
-
Northwell Heatlh/Lenox Hill Hospital
RECRUITINGNew York, New York, 10075, United States
Contact
Contact
Conditions
Explore the condition pages connected to this study.